Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001278-26

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase I • To determine the safety and tolerability of pazopanib and lapatinib when administered in combination with EIAC in patients with recurrent Grade III or IV malignant gliomas. • To determine the OTR of pazopanib and lapatinib when administered in combination with EIAC. Phase II • To determine PFS at 6 months in patients with recurrent Grade IV malignant gliomas who are receiving pazopanib and lapatinib. Patients will be enrolled into 1 of 2 strata. One stratum will consist of patients with tumors that express EGFRvIII and/or PTEN, and the other stratum will consist of patients with tumors that express neither molecular marker. • To determine the safety and tolerability of pazopanib and lapatinib when administered to patients with recurrent Grade IV malignant gliomas.


Critère d'inclusion

  • Relaped Malignant Glioma = patients with anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme or gliosarcoma at recurrence

Liens